short answer is no. Sigmisminicolonoscopy doesn't matter. It's a test that EXAS will almost completely replace shortly. By 2008 almost no docs will be using Sigmoidoscopyn as a screening method. Docs have all been waiting for a non-invasive dna based test for several years (for other things as well). Once pg+ is in guidelines later this year likely, insurance companies will practically require it before a colonoscopy or other more costly medical procedure for most of the population. Think about this. For the cost of one colonoscopy, the insurance companies can see about 5x or 6x more people screened with pg+. What does everybody think the insurance company actuaries are thinking about how much that reduces their exposure to costly cancer treatment? They're thinking they're going to save a lot of loot. EXAS has the only dna based screening test close to mass market. My guess is EXAS will have a 3-5 year headstart on competitors. Market is huge.